DOSAGE INDEX / SINGLE
Kisspeptin
Research, reported schedules and supply planning.
Review kisspeptin-10 and kisspeptin-54 human research on hormones, IVF, sexual desire and anxiety, with clear safety and evidence limits.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 100–200 micrograms per day
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks
- Route / research model
- Subcutaneous
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 10 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- In the 2011 study, intravenous kisspeptin-10 produced an acute LH response. Small infusion experiments also found increases in testosterone and LH pulse characteristics. Individual experimental groups were small; the lower-rate infusion analysis reported four participants. [1]
- A 2014 study enrolled 53 women undergoing IVF. Kisspeptin-54 was administered after ovarian stimulation and GnRH-antagonist treatment. Egg maturation was observed, and fertilization with embryo transfer occurred in 49 participants. The reported clinical-pregnancy proportion was 12 of 53. [2]
- The 2022 randomized crossover study involved premenopausal women with hypoactive sexual desire disorder. Thirty-two of 40 randomized participants completed both visits. Kisspeptin-54 altered responses in brain regions during erotic and attraction tasks. The researchers reported no adverse effects in this short experimental setting. [3]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 17 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Original results
- Original IVF study
- Original female trial
- Endocrine Reviews (Oxford Academic)Further reading · Listed in reference bibliography.
- Journal of Clinical InvestigationFurther reading · Listed in reference bibliography.
- U.S. Food and Drug AdministrationRegulatory / product information · Listed in reference bibliography.
- Clinical Procedures for Safer Patient CareFurther reading · Listed in reference bibliography.
- CDC Vaccine Administration GuidelinesGeneral guidance · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.